- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Gerard Anderson: Improving Access to Care Can Help Drive Costs Down
The public health community, the provider community, and the general public need to help the pharmaceutical industry increase access to services and put downward pressure on costs, said Gerard Anderson, PhD, of Johns Hopkins Bloomberg School of Public Health.
The public health community, the provider community, and the general public need to help the pharmaceutical industry increase access to services and put downward pressure on costs, said Gerard Anderson, PhD, of Johns Hopkins Bloomberg School of Public Health.
Transcript (slightly modified)
What impact could the recent spotlight from patients, lawmakers, and even the president, have on the price of pharmaceuticals?
I think what the pharmaceutical industry needs is some way to get the quantity up. Right now, they don’t have any mechanisms because they really can’t do very much.
I think the public health community, the provider community, and the general public, needs to do something to help the pharmaceutical industry to get their quantity up. They’re modeling their assumptions that only 10% to 15% of the population is going to get a particular drug and that is how they have generated their revenue estimates. So, if we can just make it that they get the same revenue, but with 60% to 80% of the people getting that same drug, we are all better off—but right now we can’t do it.
So, I think that the idea for me, is to improve access to care by helping the pharmaceutical industry increase the access to services.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More
